Bromocriptine
Mechanism :
Being a dopamine agonist, it stimulates dopamine receptors, inhibits anterior pituitary prolactin secretion.
Indication :
- Hyperprolactinemic states.
Contraindications :
Uncontrolled hypertension and sensitivity to any ergot alkaloids, uncontrolled hypertension.
Avoid abrupt withdrawal of the drug.
Dosing :
Orally with food
>11 years: 1.25-2.5 mg once a day initially, may increase the dose over 2-7 days by 2.5 mg/day (Dose range: 2.5-10 mg daily). Taper dose gradually until it is discontinued.
Adverse Effect :
Nausea, headache, dizziness, fatigue, light headedness, vomiting, abdominal cramps, nasal congestion, GI upset, drowsiness, cerebrospinal fluid rhinorrhea.
Interaction :
Alcohol: The risk of using Bromocriptine in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of Bromocriptine.
Dopamine Antagonists, Butyrophenones, and certain other agents: Bromocriptine may interact with dopamine antagonists, butyrophenones, and certain other agents.
Phenothiazines, Haloperidol, Metoclopramide, Pimozide: Compounds in these categories result in a decreased efficacy of Bromocriptine.
Other Ergot Alkaloids: Concomitant use of Bromocriptine with other ergot alkaloids is not recommended.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
20-50 | Dose as in normal renal function |
10-20 | Dose as in normal renal function |
<10 | Dose as in normal renal function |
Dose in Patients undergoing Renal Replacement Therapies
CAPD | Not dialysed. Dose as in normal renal function |
HD | Not dialysed. Dose as in normal renal function |
HDF/High flux | Unknown dialysability. Dose as in normal renal function |
CAV/VVHD | Not dialysed. Dose as in normal renal function |
Hepatic Dose :
Bromocriptine is metabolized by the liver. Use with caution in hepatic impairment as concentrations of bromocriptine may increase. Dose adjustment may be required.